Author:
Ahmad Sahil,Gupta Sudheer,Kumar Rahul,Varshney Grish C.,Raghava Gajendra P. S.
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Rubin, I. & Yarden, Y. The basic biology of HER2. Ann. Oncol. 12 Suppl 1, S3–8 (2001).
2. Morrow, P. K. H., Zambrana, F. & Esteva, F. J. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. 11, 207 (2009).
3. Vu, T. & Claret, F. X. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62 (2012).
4. Pohlmann, P. R., Mayer, I. A. & Mernaugh, R. Resistance to Trastuzumab in Breast Cancer. Clin. Cancer Res. 15, 7479–7491 (2009).
5. De, P., Hasmann, M. & Leyland-Jones, B. Molecular determinants of trastuzumab efficacy: What is their clinical relevance? Cancer Treat. Rev. 39, 925–34 (2013).
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献